Superdrug given wider scope in Europe

Superbugs, beware. European regulators have unleashed the Novartis drug Cubicin on two more dangerous hospital-acquired infections, including those caused by multidrug-resistant staph, or MRSA. Cubicin is first in a new class of antibiotics known as cyclic lipopeptides designed to prevent bacteria from releasing toxins into the bloodstream.

The two new indications approve Cubicin for use against staph infections of the heart valve and bloodstream. Studies showed the drug as equally effective as current standard-of-care treatments with vancomycin or penicillin-plus-gentamicin - with fewer instances of impaired kidney function, the company said.

- check out the Novartis press release
- and here's more from CNN Money 

Related Articles:
Cubist seeks expanded label for Cubicin. Report
Drug-resistant superbugs drive blockbuster antibacterials
. Report
Indian court spurns Novartis on patent challenge. Report
NCI cancels Novartis cancer study. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.